We invites submissions to the Collection “Advances in Acute Myeloid Leukemia (AML) Therapy in the Precision Medicine Era.” Submission deadline: 19 Feb 2027 buff.ly/xsqkygl #AML #PrecisionOncology #HematologicMalignancies #MRD

A study across Brazil, Mexico, and Peru examines how fertility concerns influence acceptance of (neo)adjuvant chemotherapy among young women with early-stage #BreastCancer, highlighting gaps in awareness and access to fertility preservation. buff.ly/W1gWits #OncoFertility #CancerCare #LatinAmerica

📣 If you will be at #ESTRO26 please connect with my team member Applonia! She is alsI Editor of the journal Technology in Cancer Research & Treatment which has a significant focus on radiation oncology research. #oncosky #oncology #radiotherapy #ESTRO2026

📣 Call for Papers - Volume 2 Following the success of Volume 1, Ther Adv Med Oncol launches Volume 2 of this Collection on #ADC in #BreastCancer, focusing on new standards, emerging challenges, and future directions. Deadline: 29 Jan 2027 journals.sagepub.com/topic/collec... #MedicalOncology

Resistance to second‑generation AR pathway inhibitors remains a key challenge in #ProstateCancer. This review explores mechanisms of resistance and emerging third‑generation strategies, including AR degraders and steroid biosynthesis inhibitors. buff.ly/dDwk7Tz #AndrogenReceptor #PrecisionOncology

Call for papers: a new collection in Ther Adv Med Oncol focuses on immunotherapy for T‑cell malignancies, spanning checkpoint inhibition, ADCs, bispecifics, cellular therapies, biomarkers, and resistance mechanisms. buff.ly/y2kbSVy #HematologicMalignancies #Immunotherapy #TCellLymphoma

Genomic profiling is reshaping research strategies in cervical, vulvar & vaginal cancers. This review summarises molecular features across tumour types and examines emerging targeted and combination approaches, including #ADC. buff.ly/EP7cYS5 #GynOnc #PrecisionOncology #CancerGenomics

A new Collection in Ther Adv Med Oncol examines how biomarker‑driven strategies are shaping lung cancer care across the disease continuum. Deadline: 29 Jan 2027 buff.ly/RrkerAu #LungCancer #PrecisionOncology #Biomarkers #MedicalOncology

#ADCs are reshaping breast oncology, alongside new questions on sequencing, biomarkers, and toxicity management. Explore this Ther Adv Med Oncol special collection, guest edited by Paolo Tarantino, MD, and Ilana Schlam, MD. buff.ly/pZycpW5 #BreastCancer #ADCs #MedicalOncology #OncologyResearch

A new Special Collection in Ther Adv Med Oncol will explore emerging treatment strategies in HR+HER2‑ advanced #BreastCancer, a field marked by rapid therapeutic expansion and ongoing unmet need. Submission deadline: 14 Dec 2026 buff.ly/Da8ENXI #HRpositive #HER2negative #MedicalOncology

A real‑world retrospective study in Ther Adv Med Oncol examined the prevalence of HER2‑ultralow disease in HR+/HER2‑negative metastatic breast cancer and reported comparable first‑line chemotherapy outcomes to HER2‑low disease. buff.ly/Q7JaadR #BreastCancer #HER2 #MedicalOncology #RealWorldEvidence

Ther Adv Med Oncol announces an open call for a Special Collection on Advances in Clinical Care for Glioblastoma. We welcome clinically actionable research across the care pathway, from diagnostics to patient‑centered outcomes. buff.ly/8jRyYqj #Glioblastoma #NeuroOncology #MedicalOncology

A dual‑center study in Ther Adv Med Oncol evaluated the Systemic Inflammation‑Nutrition Index (SINI) as a predictor of pathological response and relapse‑free survival in locally advanced #GIST treated with neoadjuvant imatinib. buff.ly/fKecUtx #Sarcoma #MedicalOncology #TargetedTherapy

Ther Adv Med Oncol announces an open call for a Special Collection on Modern Approaches to Patient Selection in Breast Cancer. Submissions addressing biomarkers, computational tools, and integrated clinical strategies are welcome. buff.ly/t6TEH5G #BreastCancer #MedicalOncology #PrecisionOncology

A dual‑center study evaluates the systemic inflammation–nutrition index (SINI) as a predictor of pathological response and prognosis in locally advanced #GIST treated with neoadjuvant imatinib. A SINI‑based nomogram showed strong discrimination. buff.ly/pvg142X #Sarcoma #Imatinib #Biomarkers

🚨 Call for Papers! Our new Special Collection in Ther Adv Med Onc - Advances in Biomarkers for Genitourinary Cancers - is now open. 🗓 Deadline: 6 Nov 2026 🔗 Submit here: buff.ly/sQgaDWS #Oncology #GUcancer #Biomarkers #ProstateCancer #BladderCancer #KidneyCancer

Ther Adv Med Oncol: Second‑line mFOLFIRINOX outperformed SOX after gemcitabine+nab‑paclitaxel failure in advanced PDAC (n=113): • OS 10.4 vs 6.1 mo • PFS 4.8 vs 2.4 mo But with higher grade ≥3 AEs. 🔗https://buff.ly/QwPfnx9 #PancreaticCancer #GIOnc

🚨 Call for Papers! Ther Adv Med Onc invites submissions to our Special Collection on combined immunotherapy for advanced HCC. 🗓 Deadline: 30 Oct 2026 🔗 Submit: buff.ly/e8XA6kU #HCC #LiverCancer #Immunotherapy #Oncology

Ther Adv Med Oncol: A review highlights maintenance therapy as a strategy to extend benefit after first‑line anthracyclines in advanced soft tissue #sarcoma. PLD emerges as a promising continuation option with reduced cardiotoxicity. Read: 【🔗https://buff.ly/tV2uyCE 】 #STS #Oncology

📣 Call for Papers Novel Approaches to High‑Risk HER2+ Early‑Stage Breast Cancer - a new Special Collection in Therapeutic Advances in Medical Oncology - is now open. 🗓 Deadline: 4 Dec 2026 🔗 buff.ly/3jv7zmw

A large retrospective cohort shows CLDN18.2 expression does not influence outcomes of first‑line immunochemotherapy in HER2‑negative, pMMR, PD‑L1 CPS≥1 metastatic gastric/GEJ cancer. 🔗 buff.ly/rdAewUh #GastricCancer #Immunotherapy #CLDN182 #Biomarkers

🚨 Call for Papers – Special Collection: Precision Immuno‑Oncology We welcome original research, clinical trials, reviews, and real‑world evidence shaping precision cancer care. Guest Editor: Dr. Peng Luo 🔗 Submission details: buff.ly/fqWNKby #ImmunoOncology #PrecisionMedicine #Biomarkers

A rev in Ther Adv Med Onc highlights the unique challenges of early breast cancer in young BRCA carriers-covering surveillance, risk‑reducing surgery, PARP‑based therapy, fertility considerations, and survivorship needs. 🔗https://buff.ly/6fj4pvT #BreastCancer #BRCA #Oncology #YoungPatients

A review in Ther Adv Med Onc summarizes major advances in SCLC: chemo‑IO as standard in ES‑SCLC, durvalumab approved for LS‑SCLC, emerging options for relapse (lurbinectedin, tarlatamab), and evolving biomarkers/transcriptional subtypes. 🔗https://buff.ly/LoHtjYT #SCLC #LungCancer #Immunotherapy

Real‑world evidence in Ther Adv Med Onc shows nal‑IRI/5‑FU/LV significantly improves OS in pancreatic adenocarcinoma (28.0 vs 18.3 months) despite higher cost (ICER $33,285/LYG). 🔗https://buff.ly/dOq2XvY #PancreaticCancer #GIOnc #RealWorldEvidence #HealthEconomics

French consensus published in Ther Adv Med Onc-provide practical, real‑world guidance to prevent and manage hematologic toxicities from PARPis in metastatic PC-an area of growing need. 🔗 Full article: buff.ly/9fa08rG #ProstateCancer #mCRPC #PARPInhibitors #Oncology

ctDNA findings from the Ni‑High phase Ib trial: ERBB2 focal amplification and early mMAF decline strongly predict improved outcomes with trastuzumab + nivolumab + chemo in HER2+ aGC. 🔗https://buff.ly/S2kBuFe #GastricCancer #HER2 #ctDNA

Real‑world, 8‑year multicancer study of lenvatinib shows manageable long‑term use across DTC, AdCC, HCC & EC. Notably, BMI declined during treatment (p=0.045), highlighting the need for closer monitoring in low‑BMI patients. 🔗 buff.ly/Ckygpuz #Lenvatinib

Review on pregnancy & breast cancer in young women: PrBC vs PPBC distinctions, chemo during pregnancy (incl. taxanes after 1st trimester), POSITIVE trial on ET interruption, and fertility preservation gaps for targeted agents. 🔗 buff.ly/ZDZelh2 #BreastCancer #YWBC

Review: Histologic transformation is a key mechanism of resistance in driver‑positive NSCLC, leading to aggressive SCLC, squamous, or neuroendocrine phenotypes.⬇️ summarize mechanisms and treatment options. 🔗 buff.ly/jJq7xOQ #NSCLC #LungCancer #Oncology #TargetedTherapy

A Phase IV real‑world analysis examined fruquintinib safety in two under‑studied CRC populations in China: young adults (<50) and the late‑elderly (≥75). Safety events were comparable between age groups, supporting broad applicability. buff.ly/1Wpdefh #ColorectalCancer

New real‑world evidence on Utidelone (UTD1) for mBC In a multicenter retrospective study of 270 pts, UTD1, used mainly in combination regimens, showed encouraging effectiveness in heavily pretreated populations. Link: buff.ly/nayTcuy #BreastCancer #MBC #Oncology

Doublet vs triplet chemo in advanced gastric & GEJ cancer: which wins? Multi-center study (493 pts) compared mFOLFOX-6 vs mDCF. Results: Similar efficacy (ORR ~37%, PFS 6 - 7 mo, OS ~12 mo), but mFOLFOX-6 had fewer grade 3-4 hematologic toxicities. 🔗https://buff.ly/UvoGGkJ

Can carboplatin AUC10 replace cisplatin in metastatic good-risk seminoma? Updated multi-centre study (236 pts, 21 yrs) shows 5-year PFS 89%, OS 93% with carboplatin AUC10. Elevated LDH predicts worse outcomes, but survival remains comparable. 🔗 buff.ly/3bOeiMh

How deep should PSA go in mCSPC? ⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design? 🔗 buff.ly/zGZ7FfA #ProstateCancer #Oncology #mCSPC #PSA #CancerResearch

NSCLC remains the leading cause of cancer mortality. This review explores how IO is being integrated into neoadjuvant, perioperative & adjuvant settings to reduce recurrence and improve survival. 👉https://buff.ly/ZsztUQH

🔍 Study on Tissue Factor (TF) in salivary gland carcinoma (SGC)! SGC is a rare head & neck cancer with diverse molecular profiles. This study analyzed TF expression in 109 patients and its link to clinicopathological features. 👉 buff.ly/6E30XWj

🔍 Review on HCC & lenvatinib response prediction! HCC remains highly lethal, and while lenvatinib is a first-line option, not all patients benefit. This review explores biomarkers that predict response, aiming to guide personalized treatment. 👉https://buff.ly/xIRqZb2

Gut microbiome matters in lymphoma care! 🦠 It shapes responses to chemo, CAR-T, and stem cell transplant. Antibiotic use can disrupt this balance - future therapies may restore it. 🔗 Read more: buff.ly/pVU90WF #Lymphoma #Microbiome #CancerResearch

BMI and weight change ≠ survival predictors in mTNBC patients on sacituzumab govitecan. Real-world Polish data show no link to PFS, OS, or AEs. 🔗 Read more: buff.ly/kHtlvYH #BreastCancer #mTNBC #Oncology

TROP2 is almost universal in OSCC (96.5% positive; 84.1% moderate-high), while Nectin-4 appears in 38.8% - higher in HPV-positive cases. Promising ADC targets! 🔗 Read more: buff.ly/nH3QbYa #HeadNeckCancer #TargetedTherapy #Oncology

KRAS mutations matter! 🧬 In a cohort of 1667 advanced solid tumors, 28.1% had KRAS aberrations. G12D was most frequent (40.6%), and G12V/G13D linked to poor survival. 🔍 Learn more: buff.ly/Z7QSjPx #Oncology #KRAS #CancerResearch

Happy Holidays and a healthy New Year from Therapeutic Advances in Medical Oncology. Thank you to our authors, reviewers, EBMs, and readers for advancing cancer research in 2025 - we look forward to sharing more breakthroughs in 2026. #HappyNewYear #Oncology buff.ly/m1hvWDs

👵🧬 Gastric cancer is rising among elderly patients, posing unique treatment challenges. This review explores systemic therapy strategies, geriatric assessments, and emerging targeted options. Read more: buff.ly/H2tEtBs #Oncology #GastricCancer #GeriatricOncology

A multicenter study of 33 advanced EC tumors treated with ICIs reveals: MMRd/MSI‑H tumors show ~81% TLS/LA vs 17% in MMRp/MSS, with strong CD8–B cell interactions; Low stromal CD68⁺ TAM density strongly predicts ICI response (OR=11.7; AUC=0.75) 🔗 Read more: buff.ly/3GlHjtf #EndometrialCancer

Capivasertib+Fulvestrant:a new targeted approach for HR⁺, HER2‑low/negative aBC, esp with PI3K/AKT/PTEN pathway alterations. Backed by FAKTION and Capitello 291, this combo shows strong efficacy and manageable safety. FDA approved 2023; NICE followed 2025. 🔗 Read more: buff.ly/yfdhSNi #BreastCancer

📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO 👉 Watch on demand and stay at the forefront of oncology. #esmomeetings 🔗 https://ow.ly/7MwC50XHrLB

Gastric-type endocervical adenocarcinoma is highly aggressive with poor prognosis. Immunoscore predicts survival, while Claudin 18.2 & PD-L1 offer potential therapeutic targets. #Oncology #CancerResearch buff.ly/7K5gpdI

Menopause-related side effects are common in young women with HR+ early breast cancer on ovarian suppression + endocrine therapy. Hot flashes, night sweats, sleep issues & anxiety worsen over time, especially in women <40. Clinical care must address QoL. #BreastCancer buff.ly/6mZJSAr

ICI combos are reshaping hepatocellular carcinoma care. Phase III trials (IMbrave050, EMERALD-1, LEAP-012) show promise in resectable & embolization-eligible settings, but survival benefits remain unclear. More research is needed. #CancerResearch 🔗 Read the article: buff.ly/kbZ7ewQ